Armistice Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Armistice Capital’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-300,000	Closed	-$4.02M	–	87
2019 Q1	$4.02M	Buy	+300,000	New	+$3.42M	0.22%	58
2015 Q4	–	Sell	-506,000	Closed	-$7.79M	–	44
2015 Q3	$7.79M	Buy	+506,000	New	+$10.9M	2.66%	19

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital's FPRX Position: Q2 2019 in Review

Armistice Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2019, closing a stake of 300,000 shares — an estimated $4.02M sold.

Armistice Capital first reported a position in FPRX in Q3 2015 and held it in 2 quarters. The position peaked at $7.79M in Q3 2015. 114 funds tracked by Wall St. Rank hold FPRX as of Q2 2019.

Armistice Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Armistice Capital sold 300,000 Five Prime Therapeutics, Inc. shares in Q2 2019, an estimated $4.02M.
Armistice Capital first reported a position in Five Prime Therapeutics, Inc. in Q3 2015 and held it in 2 quarters.
Armistice Capital's Five Prime Therapeutics, Inc. position peaked at $7.79M in Q3 2015.
114 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2019.

Based on Armistice Capital's 13F filing for Q2 2019, filed 14 Aug 2019.